此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

脑转移瘤的 RAPId SimPLE 靶向放射治疗 (RAPPLE)

2026年9月16日 更新者:British Columbia Cancer Agency

5 天与 1 天 RAPId SimPLE (RAPPLE) 靶向放射治疗脑转移瘤的随机 II 期非劣效性研究

The aim of the study is to show that rapid, simple targeted radiotherapy to brain metastases with 8 Gy / 1 is non-inferior to 20 Gy / 5 in terms of overall survival for patients with poor prognosis.

研究概览

地位

主动,不招人

详细说明

Hypothesis For selected patients with limited life expectancy, a single targeted fraction of 8 Gy / 1 to brain metastases will provide equivalent survival as targeted radiotherapy with 20 Gy / 5 to brain metastases.

Justification The QUARTZ study randomized patients with brain metastases and poor prognosis between 20 Gy / 5 whole brain radiotherapy (WBRT) and best supportive care. The median survival in both arms of the study was 9 weeks. The quality of life in both arm was also the same. It is known that WBRT significantly diminishes quality of life. The investigators interpretation of the QUARTZ trial is that the unchecked growth of brain metastases in the best supportive care arm diminishes quality of life as much as WBRT. To control brain metastases without giving WBRT, targeted treatment with 20 Gy / 5 to the metastases alone is standard care at BC Cancer. Numerous randomized trials have compared the efficacy of 20-30 Gy / 5-10 fractions and 8 Gy / 1 for palliative treatment of pain from bone metastases. In addition, there is a randomized trial showing that 20 Gy / 5 and 8 Gy /1 are equally effective for the treatment of symptoms from spinal cord compression. This study will test the use of this shorter, one-visit treatment schedule against the standard 5-visit treatment schedule for patients with brain metastases.

Research Design Randomized Phase II Non-Inferiority Study. The estimated median survival for this cohort, based upon a prior cohort study from 2012-2016 at BC Cancer is 3 months (13 weeks). The investigators would regard a study median survival of less than the 9-week median survival observed in the QUARTZ trial as unacceptable. Hence, the hazard ratio for the experimental arm and the control arm is: 13 weeks / 9 weeks = 1.44. With one-sided Type I error set at alpha = 0.2 and power = 0.8, the investigators calculated a theoretical sample size of 86 patients. Based on prior experience with clinical trials for patients with brain metastases, a 15% risk of drop-out and loss to follow up is expected. Hence the final sample size will be 100 patients. Stratification by the diagnosis-specific graded prognostic assessment (DS-GPA) ranges of 0.0 - 1.0 and 1.5 - 2.0 and lung cancer versus other histologies will help to ensure baseline characteristics that predict for equal survival are equally distributed in both arms of the study.

Statistical Analysis The primary endpoint is overall survival. The study will be considered to be a positive phase II non-inferiority study if the median survival in the experimental arm is within 4 weeks of the median survival in the standard arm.

研究类型

介入性

注册 (估计的)

100

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • British Columbia
      • Abbotsford British Columbia、British Columbia、加拿大
        • BC Cancer - Abbotsford
      • Kelowna、British Columbia、加拿大、V1Y5L3
        • BC Cancer - Kelowna
      • Prince George、British Columbia、加拿大、V2M7E9
        • BC Cancer - Prince George
      • Surrey、British Columbia、加拿大
        • BC Cancer - Surrey
      • Vancouver、British Columbia、加拿大、V5Z 4E6
        • BC Cancer - Vancouver
      • Victoria、British Columbia、加拿大
        • BC Cancer - Victoria

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 100年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Patients must fulfil all the following criteria to be eligible for admission to the study:

  • Age ≥ 18
  • Pathological diagnosis of a non-hematopoietic malignancy
  • Brain metastases of any size
  • Any number of untreated or progressing, previously treated brain metastases that can all be contoured and targeted
  • Presence of extracranial disease
  • Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) ≤ 2.0 (https://brainmetgpa.com/) or Graded Prognostic Assessment ≤ 2.0 (Appendix I)
  • Able to complete the EuroQOL (EQ-5D-5L) questionnaire
  • Willing and able to have regular imaging follow up
  • Feasible to start protocol treatment within 14 calendar days of participant enrolment
  • Karnofsky Performance Score (KPS) ≥ 50

Exclusion Criteria

Patients who fulfill any of the following criteria are not eligible for admission to the study:

  • Inability to have a brain MRI.
  • WBRT less than 3 months prior to randomization
  • Disseminated leptomeningeal carcinomatosis (limited pachymeningeal disease is permitted)
  • Multiple sclerosis
  • Neurologically declining despite corticosteroids
  • Appropriate for surgery or stereotactic radiosurgery
  • Germ cell and primary brain tumours
  • Systemic lupus erythematosis, scleroderma, or other connective tissue disorders not in remission
  • Any other serious intercurrent illness or medical condition judged by the local investigator to compromise the patient's safety, preclude safe administration of the planned protocol treatment, or prevent the patient from being managed according to the protocol guidelines
  • Pregnancy
  • Potentially fertile men or women of childbearing potential who are unwilling to employ highly effective contraception

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:20 Gy in 5 Fractions Volumetric Modulated Arc Therapy to Brain Metastases

Five treatments of 4 Gy will be delivered using volumetric modulated arc therapy on a conventional linear accelerator in a conventional head shell without the use of stereotactic radiosurgery technique.

Volumetric Modulated Arc Therapy

实验性的:8 Gy in 1 Fraction Volumetric Modulated Arc Therapy to Brain Metastases

A single treatment of 8 Gy will be delivered using volumetric modulated arc therapy on a conventional linear accelerator in a conventional head shell without the use of stereotactic radiosurgery technique.

Volumetric Modulated Arc Therapy

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Survival Time
大体时间:1 year

The median time from randomization to death

1 year

次要结果测量

结果测量
措施说明
大体时间
Median Time to Decline in Karnofsky Performance Status
大体时间:1 year

The time from randomization to a 20-point decline in Karnofsky Performance Status

1 year
Control of treated brain metastases
大体时间:1 year

Cumulative incidence of local recurrence of treated metastases

1 year
Corticosteroid use
大体时间:6 weeks

Proportion of patients taking corticosteroids

6 weeks
Control of brain disease
大体时间:1 year

Cumulative incidence of (local recurrence of treated metastases OR new metastases)

1 year
Retreatments for brain metastases
大体时间:1 year

Proportion of patients with retreatment for brain metastases after radiotherapy

1 year
Adverse Events
大体时间:1 year

Cumulative incidence of adverse events, graded using CTCAE Version 5.0

1 year
Health-Related Quality of Life
大体时间:1 year

Median time to a minimum clinically important decline in Health-Related Quality of Life

1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Alan Nichol, MD、BC Cancer Vancouver

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年7月1日

初级完成 (估计的)

2026年12月30日

研究完成 (估计的)

2027年12月30日

研究注册日期

首次提交

2021年8月4日

首先提交符合 QC 标准的

2021年9月17日

首次发布 (实际的)

2021年9月21日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月16日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅